Sidonie Golombowski-Daffner

Sidonie Golombowski-Daffner, Ph.D., was appointed Chairperson and President of Advanced Accelerator Applications (AAA), a Novartis company in October 2019. Prior to this, Sidonie was General Manager, Novartis Pharma GmbH Nürnberg and Country President Germany since 2017. In this capacity, she was also a member of the Supervisory Boards of Novartis Deutschland GmbH and Novartis Pharma GmbH, Country Executive Committee, Innovative Medicines Committee and Pharma Leadership Team Region Europe. As Country President Germany, Sidonie oversaw 7,500 associates across 12 sites, generating $3.9 billion in sales. During her tenure as General Manager of Novartis Pharma Germany, she led the marketing of products in Rare Diseases, Immunology & Dermatology, Neuroscience, Cardiology, Respiratory and Ophthalmology. Under her leadership, the team launched the first Cell and Gene therapy in the Pharma Division, Luxturna, for Ophthalmology. From 2014 to 2017, Sidonie served as Novartis Worldwide Franchise Head, Respiratory in Basel. She first joined Novartis in 2011, as Head of Primary Care for Germany. Prior to this, Sidonie spent 10 years at Sanofi and its predecessor companies, Sanofi-Aventis and Sanofi-Synthelabo in a variety of leadership positions with increasing responsibility across the pharmaceutical and generic sectors in Germany, at the corporate headquarters in France, and in the Asia-Pacific region. Sidonie first started her career as a management consultant at Roland Berger, where she spent five years advising pharmaceutical clients in the US, Europe, Russia and Japan. Sidonie holds a Ph.D. in Neuroscience from Ludwig Maximilian University of Munich (Germany) and has additional qualifications in Business Administration.

Alexandre Gibim

Alexandre Gibim was appointed Head of North America for Advanced Accelerator Applications (AAA), a Novartis company, in January 2022. He is also a member of the Novartis US Oncology Leadership Team. Prior to his appointment, Alexandre, also known as Gibim, served as the Novartis Oncology General Manager for the Greater China region since 2019. During his tenure, he led multiple, highly-successful business and portfolio transformations, achieving high double digit growth rates and doubling the workforce to 1,200 associates. Gibim also instituted a cultural transformation that led to a dramatic improvement in organizational engagement across all business functions. From 2015 to 2018, Gibim was the Country President for Novartis Brazil and General Manager of Oncology. He first joined Novartis in 2011, as the General Manager for Vaccines & Diagnostics of Novartis Brazil, holding roles of increasing responsibility over his tenure. Among his successes was the integration of a new biotech manufacturing plant. From 2010 to 2011, Gibim served as Brazil Country President and Oncology General Manager for Astellas Pharma, establishing a new market and organization for the company. Prior to this, he worked at Eli Lilly from 1994 to 2009, advancing positions across various functions including Finance, Business Development, Sales and Marketing, with additional experience in the Specialty Business and Primary Care/Pharma divisions. Gibim has developed strong multi-cultural awareness, having worked in various countries during this career, including the US, China and Brazil, and led multiple projects in Canada, Australia, Japan, Taiwan, Russia, India, Korea and Latin America. His accomplishments include performance turnarounds, culture transformations, technology transfers deals, innovative go-to-market strategies, acquisitions, and divestments. Alexandre Gibim received his Certificate in Sales & Marketing from Northwestern University – Kellogg School of Management, and a Bachelor’s degree in Business Management.

Giancarlo Benelli

Giancarlo Benelli, M.D., was appointed Head of International Markets for Advanced Accelerator Applications (AAA), a Novartis company, in November 2021. Prior to this, Giancarlo served as General Manager, AAA, first in France from 2018, with oversight of five production sites and more than 150 associates, and then in Italy where he oversaw four production sites and more than 270 associates supporting R&D, Medical, Commercial, and Market Access functions. He also served in an ad interim role as General Manager in Benelux & Switzerland in 2021. From 2014 to 2018, Giancarlo led the Novartis Oncology portfolio as General Manager of the European Central Cluster (ECC), managing all corporate and field functions in 14 countries and a staff of more than 150 associates. Giancarlo first joined Novartis Oncology in 2012, as Head of Pricing, Health Economics and Market Access, Europe, serving in that role for two years where he coordinated the pricing and reimbursement strategies and functions in all European countries. Prior to joining Novartis, Giancarlo was Vice President, Market Access, for Astra Zeneca from 2009 to 2012, and held senior management posts at Schering-Plough, IMS Health and Menarini since 1997. Giancarlo holds a Medical Doctorate degree and a Post Graduate Diploma in Thoracic Surgery, both from University of Genoa, Italy.

David Benathan

David Benathan was appointed Global Head Business Development for Advanced Accelerator Applications (AAA), a Novartis Company, in October 2019. He is also a member of the Business Development Management Team at Novartis. Prior to joining AAA, David served as Head of Business Development at AC Immune in 2018 and 2019, a publicly traded biotechnology development company active in the neurology field. From 2005 to 2018, David was Corporate Finance Director, and later Senior Director Global Business Development, for Ferring Pharmaceuticals in Switzerland, then a private company, where he led and closed multiple transactions in urology, oncology and gastro-enterology, and later developed the business units in China and Latin America. From 2000 to 2005, David was at Merck Serono, where he worked in the business planning, pipeline strategy and marketing functions within the New Therapeutic Area business unit. During his professional career, David has held increasing roles of responsibly in a broad range of healthcare industry functions, including busines operations, research, commercial and technology collaborations. Following graduation from Business School, David started his career in the financial industry as an auditor at Arthur Andersen from 1997 to 2000. David holds a Master of Science in Business and Economics from the Haute Ecole de Gestion (HEG) Lausanne, Switzerland, and completed an Executive Education program at the Oxford Business School.

Germo Gericke

Germo Gericke, M.D., Chief Medical Officer, first joined Advanced Accelerator Applications (AAA), a Novartis company in 2018, as Head of Research and Development. Prior to joining AAA, Germo served as Franchise Global Program Head in the Oncology Global Development Unit of Novartis, where he led cross-functional development activities for compounds in full development and life cycle management. Prior to moving to Oncology Global Drug Development in 2008, Germo served in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas. Germo joined Novartis in 2001 from McKinsey & Company where he was a member of the Global Healthcare Practice. Germo holds a Medical Doctorate from the University of Heidelberg. He studied medicine at Charité University Hospital, Berlin.

Elzbieta Obielecka

Elzbieta Obielecka was appointed Head of Strategy for Advanced Accelerator Applications (AAA), a Novartis company in November 2019. Elzbieta has over 15 years of cross-functional, international experience in the pharmaceutical sector. Prior to joining AAA, Elzbieta was Director, Finance and Business Planning, Worldwide Markets at Celgene since 2017. In this position, she provided strategic and financial guidance, as well as risk and opportunity assessment to leadership of Hematology-Oncology and Immune-Inflammatory franchises, representing a portfolio of more than $5 billion. Elzbieta first joined Celgene in 2014, as Associate Director, Europe, Middle East and Africa Finance & Business Planning. From 2012 to 2014, Elzbieta worked at Alcon Management SA in Geneva. She started as Commercial Manager, Distributor Markets, where she led strategy implementation and the integration process across Ciba Vision distributors after the Novartis∕Alcon acquisition, and then became Brand Manager, Daily Contact Lenses for Europe, Middle East and Africa within the Vision Care Franchise. Before this, Elzbieta worked at Ciba Vision Poland, where she was Commercial and Marketing Manager, International Distributor Markets from 2008 to 2012. Elbieta first started her career in the pharmaceutical industry in 2003, as a Sales Force Representative at Berlin Chemie-Menarini and then later at Novartis Consumer Health. Elzbieta holds a Master of Science in Nuclear Physics from the University of Lodz and additional qualifications in Business and Management from the Warsaw School of Economics (SGH), both in Poland.

Caio Kugelmas

Caio Kugelmas was appointed Managing Director and General Manager, 18F PET Diagnostics Operating Unit for Advanced Accelerator Applications (AAA) a Novartis company, in November 2021. Prior to joining AAA, Caio held positions with various Novartis businesses over the past 12 years. Most recently, he was Vice President and Chief Financial Officer of Navigate Biopharma in San Diego, California, a Novartis-owned business established in 2017, following the Genoptix divestment. Caio has held various senior finance roles at Novartis, including Vice President and Chief Financial Officer of Genoptix; Country and Pharma Chief Financial Officer for Novartis Mexico; and Regional Chief Financial Officer for Novartis Animal Health. Before joining Novartis, Caio worked for Medtronic and GE Healthcare in financial positions of increasing responsibility. Caio holds a Bachelor’s degree in Economics from Universidad Mackenzie in São Paulo, Brazil, and a Master’s in Business Administration from the University of South Carolina in the U.S.

Remo Inglin

Remo Inglin was appointed Chief Financial Officer for Advanced Accelerator Applications (AAA), a Novartis Company, in November 2021. He is also a member of the Oncology Finance Leadership Team at Novartis. Prior to joining AAA, Remo served as Lead, Environmental, Social & Governance Reporting Project for Novartis International since August 2020. From 2016 to 2020, Remo was Chief Financial Officer (CFO) for Novartis in Germany, during which time he reallocated resources behind key strategic brands and supported multiple product launches in Pharma. During the last eight months of his assignment in Germany, in addition to his CFO role, Remo was ad interim General Manager for Pharma, where he prepared the German market for product launches in respiratory and neurology. From 2014 to 2016, Remo was CFO for Novartis Pharma AG, Basel, and for Novartis Pharma Schweiz AG in Switzerland. While in these roles, he built financial teams in multiple office locations and fostered collaboration across diverse functions. Remo was Head, Finance for Novartis Pharma AG in Basel and Service Center Switzerland, from 2010 to 2014, strengthening the Finance function of the parent company, managing site services budgets and Campus investments. Remo first joined Novartis in 1991, through Sandoz Pharma AG, Switzerland, a predecessor company that later became Novartis, where he held various positions with increasing responsibility. He subsequently left in 2000, to pursue roles in the wood trading and real estate industries and with Valeant Pharmaceuticals, before returning to Novartis International AG, Basel in 2004 as Group Controller. Remo holds a Master of Science in Business and Economics from the University of Basel, Switzerland.

Ute Simon

Ute Simon, Ph.D., joined Advanced Accelerator Applications (AAA), a Novartis company as Head of Medical Affairs in April 2020, following an ad interim appointment in January 2020. Prior to this, Ute was Medical Director, Early Development & Scientific Relations, and Head Clinical Research for Novartis Pharma GmbH, Germany, since 2015. In this role, she supported the Pharma portfolio of Novartis by leading a team of 240 people across clinical development and medical affairs, with responsibility for all functional activities within clinical research, including investigator-initiated trials. During her tenure with Novartis Pharma GmbH, Germany, Ute also served as the Ad Interim Chief Scientific Officer in 2019, with oversight for country Medical Affairs, field-based Medical Science, Medical Franchise, and Trial Regulatory teams, supporting over 100 studies per year for the German market. From 2012 to 2015, Ute served as Cluster Head, Clinical Operations for Novartis Pharma GmbH, Germany, Austria and Switzerland. Prior to this, she was Group Head, Clinical Operations. Ute started her career as Lead Clinical Research Associate, Novartis Pharma GmbH, Germany, with a focus in Neuroscience and Immunology, from 2006 to 2009. Since 2013, Ute has served as a Member of the Managing Board on several German academic and industry associations, such as the German Association of Research-Based Pharmaceutical Companies, the Paul Martini Foundation (promoting drug research and scientific exchange) the Bavaria California Technology Center and the Medical University of Brandenburg. Ute earned her Ph.D., with honors, in Molecular Biology from Universität Halle an der Salle, Germany. She also studied biology and geography and holds a degree from Technische Universität Berlin.

Frédéric Collet

Frédéric Collet was appointed to the board of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. He has served as the President of Novartis France since 2017, and as Chief Executive of Novartis Oncology in France since 2015. As of 2017, he also heads the Novartis Group Executive Committee, which brings together Novartis Pharmaceuticals and Oncology, Sandoz and Alcon. Frédéric currently sits on the board of the French Pharmaceutical Industry Trade Association (LEEM), is President of the LEEM Cancer Group, and he leads the European Family. From 2009 to 2015, Frédéric was President of Sandoz France. He also served as Vice President of the French Generics and Bio-similars Professional Association (GEMME). Before this, he was General Manager of the Ciba Vision division from 2005 to 2009. Prior to joining Ciba Vision, Frédéric spent 12 years in various managerial roles within the cosmetics division of the Henkel Group. Frédéric graduated from the Institut d’´Etudes Politiques in Paris and holds a Master’s degree in Economic Science from the University of Paris II.